Neoadjuvant Treatment With the Combination of Vemurafenib and Cobimetinib (GDC-0973) in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed Phase II EADO (European Association of Dermato Oncology) Trial

Trial Profile

Neoadjuvant Treatment With the Combination of Vemurafenib and Cobimetinib (GDC-0973) in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed Phase II EADO (European Association of Dermato Oncology) Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms NEO-VC
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Feb 2017 As per Eudra study is dicontinued in Austria.status kept as per NCt, As other country(Germany) is also involved in study.
    • 11 May 2016 Planned End Date changed from 1 Apr 2017 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top